| 李柯良,李彦君,雷书悦,等.基于胰高血糖素样肽-1的多受体激动剂研究进展[J].中国临床保健杂志,2025,28(5):706-712. |
| 基于胰高血糖素样肽-1的多受体激动剂研究进展 |
| The advances of multi-receptor agonists based on glucagon-like peptide-1 |
| 投稿时间：2025-07-05 |
| DOI：10.3969/J.issn.1672-6790.2025.05.024 |
| 中文关键词: 胰高血糖素样肽1受体 代谢疾病 药物疗法 综述 |
| 英文关键词: Glucagon-like peptide 1 receptor Metabolic diseases Drug therapy Review 〖FL |
| 基金项目: |
|
| 摘要点击次数: 35 |
| 全文下载次数: 22 |
| 中文摘要: |
| 胰高血糖素样肽(GLP)-1受体是2型糖尿病及其他代谢性疾病治疗中的重要靶点。目前已有多个GLP-1受体激动剂获批应用于临床,但传统的单受体药物常存在疗效不充分、不良反应较大等缺点,基于GLP-1的多受体激动剂往往能提升药效、减小不良反应,故受到广泛关注。本文根据作用受体差异对基于GLP-1的多受体激动剂进行分类,综述基于GLP-1的双受体和三受体激动剂的研究进展,旨在为该类药物的临床应用提供参考。 |
| 英文摘要: |
| Glucagon-like peptide (GLP)-1 receptor is an important target in the treatment of type 2 diabetes mellitus and other metabolic diseases.At present,GLP-1 receptor agonists have been clinically approved.However,traditional mono-receptor drugs suffer from limited efficacy and side effects.Multi-receptor agonists based on GLP-1 could further enhance efficacy and reduce side effects,thus attracting extensive attention.This review classifies multi-receptor agonists based on GLP-1 according to the differences in targets,and summarizes the research progress of dual-and triple-receptor agonists based on GLP-1 in order to provide references for clinical application of these drugs. |
|
查看全文
|
| 关闭 |
|
|
|